TY - JOUR T1 - Neuropathic pain in the IMI-APPROACH knee osteoarthritis cohort: prevalence and phenotyping JF - RMD Open JO - RMD Open DO - 10.1136/rmdopen-2021-002025 VL - 7 IS - 3 SP - e002025 AU - Eefje Martine van Helvoort AU - Paco M J Welsing AU - Mylène P Jansen AU - Willem Paul Gielis AU - Marieke Loef AU - Margreet Kloppenburg AU - Francisco Blanco AU - Ida K Haugen AU - Francis Berenbaum AU - Anne-C Bay-Jensen AU - Christoph Ladel AU - Agnes Lalande AU - Jonathan Larkin AU - John Loughlin AU - Ali Mobasheri AU - Harrie Weinans AU - Floris Lafeber AU - Niels Eijkelkamp AU - Simon Mastbergen Y1 - 2021/12/01 UR - http://rmdopen.bmj.com/content/7/3/e002025.abstract N2 - Objectives Osteoarthritis (OA) patients with a neuropathic pain (NP) component may represent a specific phenotype. This study compares joint damage, pain and functional disability between knee OA patients with a likely NP component, and those without a likely NP component.Methods Baseline data from the Innovative Medicines Initiative Applied Public-Private Research enabling OsteoArthritis Clinical Headway knee OA cohort study were used. Patients with a painDETECT score ≥19 (with likely NP component, n=24) were matched on a 1:2 ratio to patients with a painDETECT score ≤12 (without likely NP component), and similar knee and general pain (Knee Injury and Osteoarthritis Outcome Score pain and Short Form 36 pain). Pain, physical function and radiographic joint damage of multiple joints were determined and compared between OA patients with and without a likely NP component.Results OA patients with painDETECT scores ≥19 had statistically significant less radiographic joint damage (p≤0.04 for Knee Images Digital Analysis parameters and Kellgren and Lawrence grade), but an impaired physical function (p<0.003 for all tests) compared with patients with a painDETECT score ≤12. In addition, more severe pain was found in joints other than the index knee (p≤0.001 for hips and hands), while joint damage throughout the body was not different.Conclusions OA patients with a likely NP component, as determined with the painDETECT questionnaire, may represent a specific OA phenotype, where local and overall joint damage is not the main cause of pain and disability. Patients with this NP component will likely not benefit from general pain medication and/or disease-modifying OA drug (DMOAD) therapy. Reserved inclusion of these patients in DMOAD trials is advised in the quest for successful OA treatments.Trial registration numberThe study is registered under clinicaltrials.gov nr: NCT03883568.Data are available on reasonable request. In order to gain and govern access to the central IMI-APPROACH databases, tranSMART and XNAT, access has to be approved by the IMI-APPROACH Steering Committee. ER -